Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Extracting Relevant Chemical Information from Patents with Machine Learning
Posted on October 5th, 2020 by Xuanyan Xu in Chemistry
New chemical compounds and reactions are often introduced to the world – and with little fanfare – through patents. It may be years after the patent has been filed before these compounds are published in scholarly journals, and even then it is only a small share of them that are published at all. As a result, it can be easy for these compounds to remain unknown to researchers who may be very interested in them.
(more…)To Be a Digital Pharma Player, You Need Data – Reusable Data
Posted on July 21st, 2020 by Ani Marrs in Pharma R&D
A new paper published in Drug Discovery Today finds that the pharmaceutical industry is in an “early mature” phase of using artificial intelligence in R&D, which means that major industry players are interested in and pursuing AI, but not as actively as one might expect. For instance, they note that of the top 20 pharma companies that they looked at, only two (Novartis and Johnson & Johnson) have commercialized AI through products and services so far.
(more…)The Dawn of a European Health Data Space – Opportunities
Posted on July 9th, 2020 by Mark Siebert in Pharma R&D
At the beginning of 2020, the European Commission introduced a “European strategy for data.” The document proposes to bolster and advance the data economy in Europe with a view towards capturing “the benefits of better use of data, including greater productivity and competitive markets, but also improvements in health and well-being, environment, transparent governance and convenient public services.”
(more…)Webinar: Using machine learning to identify adverse events from scientific literature
Posted on February 5th, 2020 by Umesh Nandal PhD in Pharmacovigilance
The “vigilance” aspect of the pharmacovigilance process can be very challenging. Always being on guard and knowing all of the places to look can be difficult. In a sea of information, it can even seem like a nearly impossible task to maintain awareness of all adverse events (AE). That is why there has been a lot of buzz around technologies that can help automate parts of the pharmacovigilance process.
(more…)
